How to buy Cerecor stock

Cerecor is a biotechnology business based in the US. Cerecor shares (CERC) are listed on the NASDAQ and all prices are listed in US Dollars. Cerecor employs 30 staff and has a trailing 12-month revenue of around $6.4 million.

Cerecor stock price (NASDAQ: CERC)

Use our graph to track the performance of CERC stocks over time.

Cerecor shares at a glance

• Key figures

Information last updated 2021-12-26.

52-week range	$0.00 - $0.00
50-day moving average more info button	$2.88
200-day moving average more info button	$3.01
Wall St. target price	$6.50
PE ratio more info button	N/A
Dividend yield more info button	N/A (0%)
Earnings per share (TTM) more info button	$-0.87

Buy Cerecor stocks from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.

Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.

Is it a good time to buy Cerecor stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Cerecor price performance over time

Historical closes compared with the close of $N/A from 2021-11-26

1 week (2023-01-17)	N/A
1 month (2022-12-24)	N/A
3 months (2022-10-24)	N/A
6 months (2022-07-24)	N/A

1 year (2022-01-24)	N/A
2 years (2021-01-28)	-100.00%
3 years (2020-01-28)	-100.00%
5 years (2018-01-26)	-100.00%

Cerecor financials

Revenue TTM	$6.4 million
Gross profit TTM	$-18,536,584
Return on assets TTM	-72.52%
Return on equity TTM	-213.81%
Profit margin	0%
Book value	$0.23
Market capitalisation more info button	$285 million

TTM: trailing 12 months

Cerecor share dividends

We're not expecting Cerecor to pay a dividend over the next 12 months.

Cerecor share price volatility

Over the last 12 months, Cerecor's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cerecor's is 1.4406. This would suggest that Cerecor's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Cerecor overview

Cerecor Inc. , a biopharmaceutical company, focuses on development and commercialization of treatments for rare and orphan diseases. The company develops monosaccharide therapies for the treatment of congenital disorders of glycosylation, such as CERC-801, CERC-802, and CERC-803. It is also involved in the developing of CERC-007, an anti-IL-18 monoclonal antibody for the treatment of adult onset stills disease and multiple myeloma, as well as for the treatment of systemic juvenile idiopathic arthritis; CERC-006, an oral mTORC1/2 inhibitor to treat complex lymphatic malformations; and CERC-002, an anti-LIGHT monoclonal antibody that is in phase 2 clinical trial for the treatment of COVID-19 acute respiratory distress syndrome, as well as for the treatment of pediatric-onset Crohn's diseases. In addition, the company offers Millipred, an oral prednisolone for the treatment of inflammatory conditions, such as arthritis, blood disorders, immune system disorders, skin and eye conditions, respiratory disorders, cancer, and severe allergies. Cerecor Inc. has a collaboration agreement with The Frontiers in Congenital Disorders of Glycosylation Consortium on pivotal trial of CERC-801 for the treatment of Phosphoglucomutase-1 deficiency related congenital disorders of glycosylation.

Frequently asked questions

What percentage of Cerecor is owned by insiders or institutions?
Currently 0.79% of Cerecor shares are held by insiders and 70.39% by institutions. How many people work for Cerecor?
Latest data suggests 30 work at Cerecor. When does the fiscal year end for Cerecor?
Cerecor's fiscal year ends in December. Where is Cerecor based?
Cerecor's address is: 540 Gaither Road, Rockville, MD, United States, 20850 What is Cerecor's ISIN number?
Cerecor's international securities identification number is: US05338F1084 What is Cerecor's CUSIP number?
Cerecor's Committee on Uniform Securities Identification Procedures number is: 15671L208